Immunome Inc SEC Filings

Immunome, Inc. reported full-year 2025 results and highlighted major progress across its oncology pipeline. The company posted a net loss of $212.4 million, improving from $293.0 million in 2024, on collaboration revenue of $6.9 million. Research and development expenses were $177.3 million and general and administrative expenses were $43.8 million, both reflecting higher investment and share-based compensation.

Immunome ended 2025 with cash and cash equivalents of $653.5 million, boosted by a December underwritten public offering that raised $460.5 million in gross proceeds. Management expects this cash position to fund operations into 2028.

Clinically, the Phase 3 RINGSIDE trial of varegacestat in desmoid tumors met its primary endpoint with an 84% reduction in risk of progression or death (hazard ratio 0.16, p<0.0001) and a 56% objective response rate versus 9% on placebo. Immunome plans a New Drug Application submission in the second quarter of 2026, while also advancing IM-1021, IM-3050 and multiple early-stage ADC programs toward key 2026 milestones.

Immunome, Inc. reported that investment adviser Redmile Group, LLC and its principal Jeremy C. Green beneficially own 5,718,385 shares of Immunome common stock. This stake represents 5.2% of the outstanding common shares.

The shares are held by private investment funds managed by Redmile, with Redmile and Green having shared voting and shared dispositive power over all 5,718,385 shares and no sole voting or dispositive power. The percentage is calculated using 91,710,277 shares outstanding as of November 3, 2025, plus 18,625,000 shares issued and sold as of December 18, 2025.

Redmile and Green state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Immunome. They each disclaim beneficial ownership beyond any pecuniary interest.

Immunome, Inc.'s president and CEO, who is also a director, reported buying additional company stock. On 12/18/2025, the reporting person purchased 46,511 shares of Immunome common stock at a price of $21.5 per share in an open-market style purchase that occurred in connection with the company’s recently completed underwritten public offering of common stock.

Following this transaction, the reporting person beneficially owns 853,247 shares of Immunome common stock held directly. The filing is made on behalf of a single reporting person and reflects a straightforward increase in their direct ownership stake.

Immunome, Inc. is conducting a follow-on public offering of 18,625,000 shares of common stock at $21.50 per share, for expected gross proceeds of approximately $400 million before underwriting discounts, commissions and expenses. All shares are being sold by the company, and the closing is expected on December 18, 2025, subject to customary conditions. The underwriting syndicate is led by Leerink Partners, J.P. Morgan, TD Securities (USA), Goldman Sachs & Co. and Guggenheim Securities, and they have a 30-day option to buy up to an additional 2,793,750 shares at the public offering price, less underwriting discounts and commissions.

Immunome reported positive topline results from its global Phase 3 RINGSIDE trial of varegacestat, an oral, once-daily gamma secretase inhibitor, in patients with progressing desmoid tumors.

The study met its primary endpoint of progression-free survival, cutting the risk of disease progression or death by 84% vs placebo (hazard ratio 0.16; 95% CI 0.071–0.375; p<0.0001). Confirmed objective response rate was 56% with varegacestat versus 9% with placebo, and median best tumor volume change was -83% vs +11% with placebo. All key secondary endpoints, including landmark tumor volume reduction and worst pain intensity, showed statistically significant benefits. Varegacestat was generally well tolerated, though diarrhea, fatigue, rash, nausea and cough were common, and about 55.6% of premenopausal women experienced ovarian toxicity. Immunome plans to present additional RINGSIDE data and submit a New Drug Application to the U.S. Food and Drug Administration in Q2 2026. The company also highlighted preclinical data suggesting its HC74 TOP1 inhibitor ADC payload may offer advantages over existing TOP1 inhibitor payloads.

Immunome, Inc. is offering $400,000,000 of its common stock in a public follow-on offering, and has granted underwriters a 30-day option to purchase up to an additional $60,000,000 of shares at the public offering price, less underwriting discounts and commissions.

The company plans to use the net proceeds, together with existing cash and cash equivalents, to fund the potential commercial launch of varegacestat for desmoid tumors, expand commercial development and manufacturing scale-up for varegacestat, advance clinical and preclinical oncology programs, and for working capital and general corporate purposes. A portion may also be used to in-license, acquire or invest in additional complementary businesses, technologies, products or assets.

As of September 30, 2025, Immunome had 91,706,948 shares of common stock outstanding and historical net tangible book value of $263.9 million, or $2.88 per share. Management estimates that existing cash and cash equivalents, together with the estimated net proceeds from this offering, will be sufficient to fund projected operations into 2028, though buyers face risks such as immediate and future dilution, share price volatility, an existing at-the-market program with $134.1 million capacity remaining, and the company’s intention not to pay cash dividends for the foreseeable future.

Immunome (IMNM) reported Q3 2025 results showing a net loss of $57.5 million as collaboration revenue dropped to zero after its AbbVie agreement terminated in July 2025. Operating expenses rose to $60.1 million, driven by research and development of $49.2 million and general and administrative of $10.9 million.

Cash and cash equivalents were $272.6 million at September 30, 2025, up from $143.4 million at year-end, reflecting a January 2025 public offering and sales under its at-the-market program. Total liabilities were $35.5 million and stockholders’ equity was $263.9 million. The company states its cash is sufficient to fund operations for at least 12 months from the filing date.

Year to date, net loss improved to $142.5 million from $212.7 million in 2024 as in‑process R&D charges subsided. In January 2025, Immunome issued 22,258,064 shares for net proceeds of $161.7 million. During Q3 2025 it sold 4,625,156 shares via ATM for gross proceeds of $45.9 million; $134.1 million capacity remained at quarter end. Common shares outstanding were 91,710,277 as of November 3, 2025. The pipeline advanced with a Phase 3 trial of varegacestat (topline data expected in the second half of 2025) and ongoing early-stage programs.

Immunome (IMNM) filed an 8-K announcing third-quarter results. The company reported its financial results for the quarter ended September 30, 2025 and provided a business update via a press release furnished as Exhibit 99.1.

The disclosure was made under Item 2.02 (Results of Operations and Financial Condition). The press release is furnished, not filed, which means it is not subject to Section 18 liabilities and is not incorporated into other SEC filings unless expressly referenced. The filing also lists the Inline XBRL cover page as Exhibit 104.

FMR LLC and Abigail P. Johnson report beneficial ownership of 13,056,709.11 shares of Immunome Inc. common stock, representing 15.0% of the class. The filing shows sole dispositive power over 13,056,709.11 shares and sole voting power of 13,054,983 shares for FMR LLC, with no shared voting or dispositive power reported. The statement notes that the holdings are held in the ordinary course of business and not for the purpose of changing control. A related position — Fidelity Growth Company Commingled Pool — holds 5,133,293 shares or 5.9%. The filing references an agreement in Exhibit 99 and incorporated powers of attorney for signature authority.